Supplementary File 1: SITC Immunotherapy Resistance Workshop Attendees

Ryan Sullivan, MD – Massachusetts General Hospital
Harriet Kluger, MD – Yale School of Medicine
Maria Ascierto, PhD – AstraZeneca
Sanjeeve Balasubramaniam, MD – U.S. Food and Drug Administration
Andrew Bernstein, MD, MPH – AstraZeneca
Michaela Bowden, PhD, BSc – Bristol-Myers Squibb
Margaret Callahan, MD, PhD – Memorial Sloan Kettering Cancer Center
Edward Cha, MD, PhD – Genentech, Inc.
Helen Chen, MD – National Cancer Institute
Victoria Chiou, MD – U.S. Food and Drug Administration
Charles Drake, MD, PhD – Columbia University Medical Center
David Feltquake, MD, PhD – Bristol-Myers Squibb
Robert Ferris, MD, PhD – UPMC Hillman Cancer Center
James Gulley, MD, PhD, FACP – National Cancer Institute
Shilpa Gupta, MD – University of Minnesota
Priti Hegde, PhD – Genentech, Inc.
Rachel Humphrey – CytomX Therapeutics
Patricia Keegan, MD – U.S. Food and Drug Administration
Theresa LaVallee, PhD – Parker Institute for Cancer Immunotherapy
Dung Le, MD – Johns Hopkins University
Vanessa Lucey, PhD, MBA – Cancer Research Institute
Vassiliki Papadimitrakopoulou, MD – MD Anderson Medical Center
Michael Postow, MD – Memorial Sloan Kettering Cancer Center
Eric Rubin, MD – Merck
Elad Sharon, MD, MPH – National Cancer Institute
Harpreet Singh, MD – U.S. Food and Drug Administration
Mario Sznol, MD – SITC President; Yale School of Medicine
Janis Taube, MD, MSC – Johns Hopkins School of Medicine
Hussein Tawbi, MD, PhD – MD Anderson Medical Center
Marc Theoret, MD – U.S. Food and Drug Administration
Suzanne Topalian, MD – Johns Hopkins University School of Medicine
Ashley Ward, MD – U.S. Food and Drug Administration
Roberta Zappasodi, PhD – Memorial Sloan Kettering Cancer Center